Identification of triazolam, etizolam and their metabolites in biological samples by liquid chromatography tandem mass spectrometry

Importance of the topic

Benzodiazepines such as triazolam and thienodiazepine etizolam are widely used for their sedative and anxiolytic effects and are common targets in clinical and forensic toxicology. Accurate detection of these drugs and their metabolites in biological fluids is essential for therapeutic monitoring, compliance testing and forensic investigations. The structural similarity of these compounds and their metabolites poses analytical challenges, demanding high-resolution separation and sensitive detection strategies.

Objectives and Study Overview

This study aimed to develop a high-resolution liquid chromatography-tandem mass spectrometry method capable of simultaneous quantification and identification of triazolam, etizolam and four key metabolites (alpha-hydroxytriazolam, 4-hydroxytriazolam, alpha-hydroxyetizolam and 8-ethylhydroxyetizolam). Validation was conducted using a standard mixture, an in vitro metabolized matrix and a blank human liver S9 control.

Instrumentation Used

• UHPLC System: Shimadzu Nexera
• Column: YMC-Triart C18, 1.9 μm, 150 × 2 mm
• Mobile Phase: A) 10 mM formic acid in water; B) 10 mM formic acid/acetonitrile (1:1)
• Flow Rate: 0.3 mL/min with gradient from 40% to 65% B over 40 min
• Column Temperature: 40 °C
• Mass Spectrometer: Shimadzu LCMS-8030 with ESI in positive mode
• Detection: 12 multiple-reaction-monitoring transitions with triggered product ion scans

Main Results and Discussion

• Baseline separation of triazolam, etizolam and their metabolites was achieved within 45 min.
• Blank matrices showed no interfering peaks, confirming high selectivity.
• In vitro incubations revealed seven chromatographic peaks; six corresponded to target analytes, while one additional peak provided fragmentation data for further investigation.
• MRM-triggered MS/MS spectra matched a reference library, confirming identities with high confidence.

Benefits and Practical Applications

• Reliable simultaneous screening and confirmation of benzodiazepines and metabolites in complex biological samples.
• High selectivity and sensitivity reduce false positives in clinical and forensic settings.
• Adaptable workflow for routine toxicology, drug compliance and forensic investigations.

Future Trends and Applications

• Extension to additional benzodiazepine analogues and emerging psychoactive substances.
• Integration with high-resolution mass spectrometry for accurate mass measurement and broader screening.
• Automation of sample preparation and data processing to increase throughput.
• Development of miniaturized and point-of-care LC-MS platforms for rapid field testing.

Conclusion

The described UHPLC-MS/MS method delivers high-resolution separation and sensitive detection of triazolam, etizolam and their metabolites in biological matrices. Optimized MRM transitions combined with triggered MS/MS scans ensure confident identification and quantification, supporting diverse applications in clinical and forensic toxicology.

References

1. Shoji N, Minohata T, Kuriyama N, Yokoyama C, Matsumoto K, Watanabe J, Iida J. Identification of triazolam, etizolam and their metabolites in biological samples by liquid chromatography tandem mass spectrometry. ASMS 2012; WP28-611.
2. YMC Co. YMC-Triart C18 Column Technical Manual.
3. Shimadzu Corporation. LCMS-8030 Operator’s Guide.